NAPWA

The quadrivalent human papillomavirus (HPV) vaccine (Gardasil) prevents infection and disease in men, according to data presented by Dr Heiko Jessen from Berlin.

In fact, the efficacy(Of a drug or treatment). The maximum ability of a drug or treatment to produce a result regardless of dosage. A drug passes efficacy trials if it is effective at the dose tested and against the illness for which it is prescribed. In the standard procedure, Phase II clinical trials gauge efficacy, and Phase III trials confirm it. data was so good that the US Food and Drug AdministrationThe U.S. Department of Health and Human Services agency responsible for ensuring the safety and effectiveness of all drugs, biologics, vaccines, and medical devices, including those used in the diagnosis, treatment, and prevention of HIV infection, AIDS, and AIDS-related opportunistic infections. The FDA also works with the blood banking industry to safeguard the nation's blood supply. The Australian equivalent is the Therapeutic Goods Administration (TGA). stopped the trial early so that men in the placeboA dummy medical treatment, designed to have no pharmacological effect, administered to the control group of a clinical trial. group could get the vaccine.

The trial started out with more than 4000 healthy men aged 16 to 26 years from 18 countries (including 200 men who have sex with men) and followed them for three years.

The researchers detected three external genital lesions related to HPV types 6, 11, 16 or 18 in the vaccine armAny of the treatment groups in a randomised trial. Most randomised trials have two "arms," but some have three "arms," or even more. and 31 in the placebo arm.

There were no cases of penile, perianal or perineal intraepithelial neoplasia, but one wouldn't expect these in young healthy men during a short follow-up trial, added Dr Jessen. The research team will continue to follow the participants.

‘For now, it makes sense to give the HPV vaccine to boys and men aged 9 to 26,’ he said, but his group intends to examine its efficacy in older men as well, particularly in men who have sex with men, who are at higher risk for HPV-related malignancy.